TW200510424A - Treatment of male sexual dysfunction - Google Patents

Treatment of male sexual dysfunction

Info

Publication number
TW200510424A
TW200510424A TW093121513A TW93121513A TW200510424A TW 200510424 A TW200510424 A TW 200510424A TW 093121513 A TW093121513 A TW 093121513A TW 93121513 A TW93121513 A TW 93121513A TW 200510424 A TW200510424 A TW 200510424A
Authority
TW
Taiwan
Prior art keywords
treatment
sexual dysfunction
male sexual
ejaculation
relates
Prior art date
Application number
TW093121513A
Other languages
English (en)
Chinese (zh)
Inventor
Christopher Peter Wayman
Rachel Jane Russell
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TW200510424A publication Critical patent/TW200510424A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
TW093121513A 2003-07-23 2004-07-19 Treatment of male sexual dysfunction TW200510424A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0317227.7A GB0317227D0 (en) 2003-07-23 2003-07-23 Treatment of male sexual dysfunction

Publications (1)

Publication Number Publication Date
TW200510424A true TW200510424A (en) 2005-03-16

Family

ID=27772516

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093121513A TW200510424A (en) 2003-07-23 2004-07-19 Treatment of male sexual dysfunction

Country Status (12)

Country Link
EP (1) EP1656183B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006528171A (cg-RX-API-DMAC7.html)
AT (1) ATE380048T1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0412255A (cg-RX-API-DMAC7.html)
CA (1) CA2533177A1 (cg-RX-API-DMAC7.html)
CL (1) CL2004001702A1 (cg-RX-API-DMAC7.html)
GB (1) GB0317227D0 (cg-RX-API-DMAC7.html)
MX (1) MXPA05014200A (cg-RX-API-DMAC7.html)
TW (1) TW200510424A (cg-RX-API-DMAC7.html)
UA (1) UA79674C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005006899A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200505957B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117414361A (zh) * 2023-09-28 2024-01-19 华中农业大学 一种化合物在预防和治疗革兰氏阴性菌病方面的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
GB0504556D0 (en) * 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
JP2008533192A (ja) * 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシンアンタゴニストとしての置換されたトリアゾール誘導体
US20220152032A1 (en) * 2020-11-13 2022-05-19 Pharma America Holding Inc. Sexual therapy formulation and method of treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2000223275A1 (en) * 2000-02-08 2001-08-20 Yamanouchi Pharmaceutical Co..Ltd. Novel triazole derivatives
GB0224919D0 (en) * 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117414361A (zh) * 2023-09-28 2024-01-19 华中农业大学 一种化合物在预防和治疗革兰氏阴性菌病方面的应用

Also Published As

Publication number Publication date
CL2004001702A1 (es) 2005-05-13
CA2533177A1 (en) 2005-01-27
UA79674C2 (en) 2007-07-10
EP1656183A1 (en) 2006-05-17
ATE380048T1 (de) 2007-12-15
WO2005006899A1 (en) 2005-01-27
BRPI0412255A (pt) 2006-09-19
MXPA05014200A (es) 2006-07-03
ZA200505957B (en) 2006-11-29
GB0317227D0 (en) 2003-08-27
JP2006528171A (ja) 2006-12-14
EP1656183B1 (en) 2007-12-05

Similar Documents

Publication Publication Date Title
MXPA06014798A (es) Antagonistas del receptor de hormona para liberar gonadotropina.
MXPA03007513A (es) Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
IL182090A0 (en) 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists
TW200510301A (en) Novel compounds
TW200510303A (en) Novel compounds
SG122820A1 (en) Process for the distillation of a mixture of isomeric diisocyanatodiphenylmethanes
ZA200408335B (en) Pyrrolidinium derivatives as antagonists of M3 muscarinic receptors.
TW200407305A (en) Novel compounds
MX337423B (es) Antagonistas anti-beta7 humanizados y usos para los mismos.
MY161834A (en) Substituted diazepan compounds as orexin receptor antagonists
TNSN07196A1 (en) Potentiators of glutamate receptors
WO2003028641A3 (en) Mch receptor antagonists
NO20050471L (no) Fremgangsmate for telomerisasjon av ikke-sykliske olefiner
GB0504828D0 (en) Therapeutic agents
CL2004000545A1 (es) Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
TW200420543A (en) Treatment of female sexual dysfunction
NO20061845L (no) Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
PL1636221T3 (pl) Związki 3-heterocyklilo-azetydynowe użyteczne jako antagoniści receptorów NK1/NK2
MX2007002393A (es) Compuestos indolicos sustituidos y su uso como moduladores del receptor de 5-hidroxitriptamina 6 (5-ht6).
WO2004056763A3 (en) Novel glucagon antagonists
TW200800959A (en) Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
MXPA05011630A (es) Metodo para aumentar la hidrofobicidad de la superficie de las tazas de inodoro.
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
PL371055A1 (en) Azetidine derivatives as ccr-3 receptor antagonists
GB0317227D0 (en) Treatment of male sexual dysfunction